E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with a diagnosis of NYHA Class II/III/IV HF for a minimum of 90 days, moderate to advanced symptoms of HF and at high risk for recurrent HF hospitalizations, characterized by having either elevated NT-proBNP or BNP within 30 days of screening and/or being hospitalized for HF within 6 months of screening |
|
E.1.1.1 | Medical condition in easily understood language |
Moderate to advanced heart failure |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010684 |
E.1.2 | Term | Congestive heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine the efficacy of a single intracoronary infusion of 1 x 10e13 DRP MYDICAR® added to an optimal HF regimen in subjects with ischemic or non-ischemic and moderate to advanced symptoms of heart failure (HF) by reducing the frequency and/or delaying HF-related hospitalizations compared to placebo-treated subjects. |
|
E.2.2 | Secondary objectives of the trial |
Assessment of the safety of MYDICAR® by determining the incidence and severity of AEs and changes in laboratory parameters. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Negative AAV1 NAb (titer <1:2 or equivocal) within 90 days of screening. 2. 18-80 years of age, inclusive, at the time of signing the informed consent. 3. Chronic systolic HF due to ischemic or non-ischemic cardiomyopathy. Subjects with ischemic cardiomyopathy must have at least one major coronary vessel with TIMI grade 3 flow. If a subject has not undergone coronary angiography with 2 months, this criterion may be assessed after the subject is randomized and undergoes angiography just prior to the planned infusion of investigational medicinal product. a. Hypertrophic cardiomyopathy is excluded. b. Toxic and alcoholic cardiomyopathies are allowed as long as toxin or alcohol exposure has been eliminated and a sufficient amount of time has elapsed to rule-out spontaneous recovery. 4. Left ventricular ejection fraction (LVEF) ≤35% anytime during the 60-day window prior to administration of investigational medicinal product. 5. Diagnosis of NYHA class II, III or IV heart failure for a minimum of 90 days prior to screening. 6. Individualized, maximal, optimized heart failure therapy consistent with American College of Cardiology/American Heart Association76 and European Society of Cardiology77,78 practice guidelines for the treatment of chronic heart failure (ACC/AHA/ESC HF guidelines) and as updated from time to time: a. Medical therapy as appropriate to the individual subject including oral diuretic, angiotensin-converting enzyme (ACE) inhibitor (or angiotensin-receptor blocker (ARB) if ACE intolerant) and as tolerated, beta blocker at approved dosages as labeled in the respective package insert. The choice of beta blocker is limited to those approved for heart failure in all participating countries (bisoprolol, carvedilol or sustained release metoprolol succinate). Unless contraindicated or not tolerated, the addition of an aldosterone antagonist should be considered in the absence of hyperkalemia and significant renal dysfunction and according to evolving standards; the final decision is at the discretion of the investigator. Dosing of the above medications must be stable for a minimum of 30 days prior to screening, although up- or down-titration of diuretics, as medically indicated, is permitted. Enrollment of any subject with any deviation from this combination must be reviewed and approved by the medical monitor. b. Resynchronization therapy, if clinically indicated according to ACC/AHA/ESC HF guidelines, must have been implanted at least 6 months prior to screening. c. Implantable cardioverter defibrillator (ICD), if clinically indicated, according to ACC/AHA/ESC HF guidelines, must have been implanted a minimum of 30 days prior to screening. d. Cardiac rehabilitation, if ongoing, should be consistent with the Agency for Health Care Policy and Research Clinical Practice Guideline, Number 17, Cardiac Rehabilitation.79 This does not imply that the potential candidate must be enrolled in a cardiac rehabilitation program now or in the future. 7. All women of childbearing potential must have a negative urine pregnancy test prior to administration of investigational medicinal product and agree to use adequate contraception (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) or limit sexual activity to vasectomized partner for 3 months after administration of investigational medicinal product. Men capable of fathering a child must agree to use barrier contraception (combination of a condom and spermicide) or limit activity to post-menopausal, surgically sterilized, or a contraception-practicing partner, for 3 months after administration of investigational medicinal product. 8. Ability to understand and comply with study requirements as evidenced by providing signed written informed consent form and Release of Medical Information Form. 9. Presence of at least one of the following risk factors: a. Hospitalization for heart failure within 6 months of screening, or in lieu of hospitalization, at least 2 outpatient interventions for the intended treatment of signs and symptoms of worsening heart failure (e.g., intravenous diuretics, peripheral ultrafiltration) b. NT-proBNP >1200 pg/mL (BNP >225 pg/mL) within 30 days of screening; if subject is in atrial fibrillation, NT-proBNP >1600 pg/mL (BNP >275 pg/mL) within 30 days of screening
|
|
E.4 | Principal exclusion criteria |
1. Any intravenous (IV) therapy with positive inotropes, vasodilators or diuretics within 30 days prior to screening. 2. Restrictive cardiomyopathy, obstructive cardiomyopathy, acute myocarditis, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease or discrete LV aneurysm. 3. Cardiac surgery, percutaneous coronary intervention (PCI) or valvuloplasty within 30 days prior to screening. 4. Myocardial infarction (e.g., ST elevation MI [STEMI] or large non-STEMI) within 90 days prior to screening. Large non-STEMI shall be defined >3x the upper limit of normal (ULN) for CK-MB or >5x ULN for troponin. 5. Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), surgically implanted LVAD or cardiac shunt. 6. Likely need for an immediate heart transplant or LVAD implant due to hemodynamic instability. 7. Prior CABG is not considered ideal for inclusion in the study; however, a potential candidate can be reviewed on a case-by-case basis. Ideally, the orifice of the graft should be easy to engage with a catheter and the graft should perfuse a significant amount of potentially viable myocardium. 8. Known hypersensitivity to contrast agents used for angiography; history of, or likely need for, high dose steroid pretreatment prior to contrast angiography. 9. Significant, in the opinion of the investigator, left main or ostial right coronary luminal stenosis. 10. Liver function tests (ALT, AST, alkaline phosphatase) >3x Upper Limit of Normal (ULN) within 30 days prior to investigational medicinal product administration or known intrinsic liver disease (e.g., cirrhosis, chronic hepatitis B or hepatitis C virus infection). 11. Current or likely need for hemodialysis within 12 months following enrollment or current GFR ≤20 mL/minute/1.73 m2 estimated by MDRD calculation. 12. Bleeding diathesis or thrombocytopenia defined as platelet count <50,000 platelets/μL. 13. Anemia defined as hemoglobin <9 g/dL, provided that there is no evidence of bleeding. 14. Known AIDS or HIV seropositive status, or a previous diagnosis of immunodeficiency with an absolute neutrophil count <1000 cells/mm3. 15. Diagnosis of, or treatment for, any cancer other than basal cell carcinoma within the last 5 years. (Past medical history of cancer is not exclusionary as long as subject has been disease-free for at least 5 years since the time of diagnosis and treatment). 16. Previous participation in a study of gene transfer; however, if the study was unblinded or documentation otherwise exists that the subject was randomized to the placebo control group and did not receive active gene transfer agent, the subject may be considered for this study. 17. Receiving investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of the investigational drug administration prior to screening. Exception may be made if the individual is enrolled in a non-therapeutic observational study (registry) or the observational portion of a therapeutic study where the sponsoring authority authorizes enrollment. 18. Pregnant or breast-feeding. 19. Recent history of psychiatric disease, including drug or alcohol abuse, that is likely, in the opinion of the investigator, to impair the subject’s ability to comply with protocol-mandated procedures. 20. Other concurrent medical condition(s) that, while not explicitly excluded by the protocol, could jeopardize the safety of the subject or objectives of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome is the time-to-recurrent HF-related hospitalizations in the presence of terminal events (all-cause death, heart transplant, MCSD implantation). Efficacy will be further assessed by the sensitivity analyses of the primary endpoint based on various definitions of the study population, various recurrent and terminal event definitions, and different methods of statistical analysis to assure that study outcome is not due to a specific statistical method, population or event definition. Sensitivity analyses for the primary endpoint will include the time-to-first clinical event (including all-cause death, heart transplant andMCSD implantation and HF-related/all–cause hospitalization) and the average rate and duration of HF-related/all-cause hospitalization over time on study. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The Primary Analysis Data Cutoff is based on a minimum length of time and cumulative total number of clinical events. Unless discontinued for a terminal event, all subjects must have completed the full 12-Month Active Observation Period and a total of at least 186 adjudicated HF-related hospitalizations have occurred. The Primary Analysis Data Cutoff will occur when both conditions have been met, whichever comes later. The Primary Analysis Data Cutoff is the trigger for locking the clinical database, unblinding the treatment assignment and performing all the planned analyses. |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy outcome is the analysis of time-to-terminal event (including all-cause death, heart transplant and MCSD implantation) based on the joint frailty model and performed simultaneously with the primary endpoint analysis. The sensitivity analyses for this secondary endpoint will be based on the following: various definitions of the study population, time-to-all-cause death analysis and a statistical approach based on the Kaplan-Meier model and log rank test. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The Primary Analysis Data Cutoff is based on a minimum length of time and cumulative total number of clinical events. Unless discontinued for a terminal event, all subjects must have completed the full 12-Month Active Observation Period and a total of at least 186 adjudicated HF-related hospitalizations have occurred. The Primary Analysis Data Cutoff will occur when both conditions have been met, whichever comes later. The Primary Analysis Data Cutoff is the trigger for locking the clinical database, unblinding the treatment assignment and performing all the planned analyses. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 34 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Denmark |
Germany |
Hungary |
Israel |
Netherlands |
Sweden |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The End of Study is when all subjects have been observed and followed for 60 months unless terminated early for any reason.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |